Streetwise Expert Interviews

Alan Leong

Tempering Insane Optimism with Due Diligence: Alan Leong on Niche Biotech Prospects

Alan Leong has chosen to look for investments positioned in less obvious alcoves of the market. Interestingly, this concept could be a competitive advantage for retail investors. His niche markets include orphan, metabolic and animal companion medicine, as well as some less obvious indications for regenerative medicine. In this interview with The Life Sciences Report, the CEO of biotech analysis company BioWatch News cites four unconventional biotech and specialty pharma names positioned to generate significant returns for investors. (7/17/14) More >

Read more Streetwise Interviews. . .

Including Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners (7/10/14) More >

Newsletter Briefs

"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >

"MSLP's transformation is not yet in the price of the stock." (7/8/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >

"THLD initiated a Phase 2 trial with TH-302 in NSCLC." (7/8/14) Threshold Pharmaceuticals Inc. - Tony Schwartz, Seeking Alpha More >

"International sales continue to be a focus for MSLP and a reason for further bullishness." (6/27/14) MusclePharm Corp. - Chris Katje, Seeking Alpha More >

"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >

"We believe BLU has a higher probability of success in its current Phase 3 Kiacta study." (6/12/14) BELLUS Health Inc. - The Life Sciences Report interview with Brian Bloom More >

"TRX is my favorite specialty pharmaceutical company right now, based on its valuation." (6/12/14) Tribute Pharmaceuticals Canada Inc. - The Life Sciences Report interview with Brian Bloom More >

Expert Analysis

"INO has initiated preparatory activities for a possible Phase 3 study." (7/15/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >

"Its current cash position should take ATNM through at least mid-2015." (7/14/14) Actinium Pharmaceuticals Inc. - Edward White, Laidlaw & Company More >

"THLD has initiated a large Phase 2 trial investigating TH-302." (7/14/14) Threshold Pharmaceuticals Inc. - Philippa Gardner, Edison Investment Research More >

"KOOL is an undervalued player with significant long-term upside." (7/8/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"BDSI's second Phase 3 buprenorphine study met its primary endpoint." (7/7/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"KOOL is positioned for fast regulatory approval and investor returns." (7/8/14) Cesca Therapeutics Inc. - Jason Kolbert, Maxim Group More >

"STEM continues to build on its strong management team." (7/7/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"BDSI announced positive top-line results from its Phase 3 study." (7/7/14) BioDelivery Sciences International Inc. - Scott Henry, ROTH Capital Partners More >